A few exceptions include that Tat-BECN1 increases unexpected synovial hyperplasia (Rockel et al., 2020) and cardiac hypertrophy (Atwood et al., 2020); it intensifies brain damage after cerebral ischemic stroke (Li et al., 2016; He et al., 2017; Zhang et al., 2017; He et al., 2019). Here, TAT is linked to cardiac hypertrophy.